RecruitingPhase 3NCT07372287

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma

Sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Enrollment

230 participants

Start Date

Jan 23, 2026

Study Type

INTERVENTIONAL

Conditions

Moderate to Severe Asthma

Summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CM326 and Placebo for people with moderate to severe asthma. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.